professor terry nolan, thank you for being with us. appreciate it.sgow in november. from milan, here is our environment correspondent victoria gill. frustration on the streets as young activists marched to the milan climate conference on friday. this is ourfuture, and we have to fight for our futures. inside the conference today, a mood of quiet formality as negotiators brought this meeting to a close. what is been discussed, though, could hardly be more urgent. the fires, the floods, the melting of the ice and the rising of the sea... the overall message from leaders here is one of cautious optimism — that it will be possible to reach a decisive climate agreement in glasgow, but that it won't be easy. people who are here in milan representing some of the most vulnerable and small island nations are really concerned that we're still a long way from the trajectory of keeping global temperature increase this century to within this key threshold of 1.5 degrees celsius. we're already in a 1.1 world. we're facing increasing frequency and severity of storm

professor terry nolan is head of the vaccine and immunisation research group at the doherty institutemes to vaccine inequality. access to supply is most important, though. the international initiative which is called covax, which has been signed up to by many of the countries and many rich governments, to contribute vaccines into an international pool, is a really important step in making those vaccines available to countries around the world. first of all, everyone should, i think, take a cold shower about all of this issue about how much of a difference is there between the vaccines. by and large, all of the vaccines are doing a very good job at controlling covid. certainly the ancestral or the initial wuhan strain, but even now with the delta strain, which is much more elusive, they're still doing a good job. there are questions of availability, of certainty about that, in some of the vaccines — for example some of the chinese vaccines, some from cuba and others where there isn't yet enough transparency in the data, either clinical trial data or data following their rollout in popu